-
Mashup Score: 0Phase 3 Data Support Enfortumab Vedotin Benefit in Previously Treated Urothelial Carcinoma - 3 year(s) ago
Recently reported data continue to support the use of enfortumab vedotin in patients with advanced urothelial carcinoma who had previously been treated with chemotherapy and immunotherapy.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Advanced RCC Shows Response to Frontline Nivolumab/Cabozantinib, Regardless of the Presence of Sarcomatoid Features - 3 year(s) ago
Compared against sunitinib, nivolumab plus cabozantinib induced better outcomes in patients with advanced renal cell carcinoma and these results were seen in patients with and without sarcomatoid features.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1PSMA-Targeted Agent Identified Disease in Majority of Patients with Relapsed Prostate Cancer - 3 year(s) ago
The potential to identify occult prostate cancer and accurately characterize disease burden was observed with the novel prostate specific membrane antigen (PSMA)–targeted radiopharmaceutical for PET imaging technique.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Pal discussed findings from the SWOG 1500 trial investigating sunitinib versus either cabozantinib, crizotinib, or savolitinib to treat patients with metastatic papillary RCC.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Patients with Cisplatin-ineligible mUC and High PD-L1 Expression Experience Clinical Benefit With Atezolizumab - 3 year(s) ago
Using the single-agent atezolizumab (Tecentriq) plus chemotherapy versus chemotherapy alone to treat patients in the front-line setting with cisplatin-ineligible IC2/3 advanced or metastatic urothelial carcinoma (mUC) revealed additional clinical evidence.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Tivozanib Increased Time Without Symptoms of Disease, Toxicity for Patients with RCC - 3 year(s) ago
As third- or fourth-line therapy for patients with metastatic RCC, tivozanib hydrochloride demonstrated a statistically significant increased quality-adjusted time without symptoms of disease and toxicity compared with sorafenib.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Professor Thomas Powles, MD @tompowles1 @Bartscancer @Q - 3 year(s) ago
Professor Thomas Powles, MD of Barts Cancer Centre, Queen Mary University of London speaks about Seattle Genetics and Astellas Announce PADCEV® (enfortuma
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Arjun Balar, MD @ArjunBalarMD @nyulangone #PerlmutterCa - 3 year(s) ago
Arjun Balar, MD from NYU Langone’s Perlmutter Cancer Center discusses Astellas and Seagen Announce Positive Topline Results from Second Cohort of Patient
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Darolutamide Remains Well-Tolerated with Prolonged Treatment Among Patients with nmCRPC - 3 year(s) ago
Darolutamide still has a favorable safety profile with prolonged treatment among patients with nonmetastatic castration-resistant prostate cancer.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Sumanta (Monty) K. Pal, MD @montypal @cityofhope #ASCOG - 3 year(s) ago
Sumanta (Monty) K. Pal, MD of the City of Hope speaks about A randomized, multi-arm comparison of targeted therapies for advanced papillary renal cell carc
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Recently reported data continue to support the use of enfortumab vedotin in patients with advanced urothelial carcinoma who had previously been treated with chemotherapy and immunotherapy. #ASCOGU21 https://t.co/r8259L8Q5k